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Abstract
Preeclampsia, a severe unpredictable complication of pregnancy, occurs in 6% of pregnancies, usually in the second or third
trimester. The specific etiology of preeclampsia remains unclear, although the pathophysiological hallmark of this condition
appears to be an inadequate blood supply to the placenta. As a result of the impaired placental blood flow, intrauterine
growth restriction (IUGR) and consequential fetal oxidative stress may occur. Consistent with this view, pregnancies
complicated by preeclampsia and IUGR are characterized by up-regulation of key transcriptional regulators of the hypoxic
response including, hif1a and as well as p53 and its target genes. Recently, the presence of circulating cell-free fetal RNA has
been documented in maternal plasma. We speculated that pregnancies complicated by preeclampsia and IUGR, will be
associated with an abnormal expression of p53 and/or hif1a related genes in the maternal plasma. Maternal plasma from
113 singleton pregnancies (72 normal and 41 complicated pregnancies) and 19 twins (9 normal and 10 complicated
pregnancies) were collected and cell free RNA was extracted. The expression of 18 genes was measured by one step real-
time RT-PCR and was analyzed for prevalence of positive/negative expression levels. Results indicate that, among the genes
examined, cell free plasma expressions of p21 and hif1a were more prevalent in pregnancies complicated by hypoxia and/or
IUGR (p,0.001). To conclude, we present in this manuscript data to support the association between two possible
surrogate markers of hypoxia and common complications of pregnancy. More work is needed in order to implement these
findings in clinical practice.
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Introduction
Preeclampsia occurs in 6% of pregnancies and is one of the
most common, dangerous, unpredictable complications of preg-
nancy [1]. The cause of preeclampsia remains unclear, although
the pathophysiology appears to be inadequate blood supply to the
placenta leading to hypoxic environment [2,3,4] which may lead
to fetal growth restriction. Intrauterine growth restriction (IUGR),
even in the absence of preeclampsia, is a challenging obstetric
complication with increased rate of fetal and perinatal morbidity
and mortality [2,4,5].
Oxygen deprivation leads to the up-regulation of genes mainly
by the hypoxia-inducible factors (HIFs) [6,7]. Hif1a is a major
regulator of cellular and systemic responses to hypoxia
[8,9,10,11,12,13]. In addition, hif1a regulates TGFb3, a target
gene induced by hypoxia both in vivo and in vitro in trophoblast cells
[14,15,16,17]. The two genes, hif1a and TGFb3 are overex-
pressed in pregnancies complicated by preeclampsia and IUGR
[15,18,19,20,21].
p53 is a central tumor suppressor gene and a major
transcriptional activator of a spectrum of genes under hypoxic
conditions [22,23,24,25,26]. In placentas of pregnancies compli-
cated by fetal growth retardation, enhanced apoptosis and up-
regulation of p53 was reported [27].
A few years ago cell-free fetal RNA was discovered in the
maternal plasma [28,29], enabling non invasive measurements of
placental/fetal gene expressions [30,31]. Given the limitations of
the current modalities, there is an urgent need for the development
of a more refined and reliable approach for fetal stress/growth
monitoring. We speculated that abnormal gene expression of p53
related genes and/or hif1a related genes may be more prevalent
with preeclampsia complicated pregnancies as well as IUGR.
Following evaluation of the expression of 18 different genes in the
maternal plasma we discovered candidate biomarkers for the
identification of complicated pregnancies and fetal growth
restriction.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37273Materials and Methods
Subject recruitment
Approval to undertake the study was granted by the institutional
human research and ethics committee. Written, informed consent
was obtained prior to subject assessment. Women were recruited
between March 2007 and September 2008 from the Obstetrics
and Gynecology department at Chaim Sheba Medical Center,
Israel. A total of 132 blood samples were collected (Table S1), 113
from singleton pregnancies (72 healthy pregnant women and 41
women with complicated pregnancies) and 19 twins (9 normal
twin pregnancies and 10 complicated twin pregnancies). The
selection criterion for complicated pregnancies was IUGR with/
without preeclampsia. IUGR was defined as birth weight below
10th centile [2,5] of customized birth weight adjusted for singleton
or multiple gestation, sex of baby and gestational age, developed
for local Israeli subjects [32]. Preeclampsia was defined as
previously described [33]. Complicated pregnancies were desig-
nated as hypoxic pregnancies (H) whereas other pregnancies were
designated as normal (N). Multiple parameters were collected for
each case including: Maternal age, weight, parity, medications,
smoking status, maternal hemoglobin concentration, fetoplacental
Doppler studies, newborn estimated and actual birth weight, 1 and
5 minutes Apgar scores.
Blood collection. 15 ml blood samples were collected from
all participants. Samples were prepared as was previously
described by Ng et al [28]. The blood samples were collected in
EDTA-containing tubes centrifuged at 1,6006g for 10 minutes at
4uC (to remove nucleated cells from the blood sample). Plasma was
then carefully transferred into 1.5 ml eppendorf tubes. The plasma
samples were re-centrifuged at 16,0006 g for 10 minutes at 4uC
and the supernatants were collected into fresh polypropylene
tubes.
Target selection. The basis for selection of candidate
biological markers was genes associated with hypoxia (Table
S2). Table S2A depicts three different target genes including:
hif1a, a key transcriptional regulator of the hypoxic response and
it’s downstream activated genes, VEGF-A (VEGF) and TGFb3
which were shown to be over-expressed in preeclampsia
[18,20,21]. Table S2B depicts p53 and fourteen downstream
p53 target genes, which were shown to be elevated by more than
10-fold following p53 activation based on previous microarray
analyses [23,24].
RNA Extraction. 1.6 ml plasma was mixed with 2 ml TRIzol
LS reagent (Invitrogen, Carlsbad, CA) and 0.4 ml chloroform as
previously described [34]. The mixture was centrifuged at
11,9006 g for 15 minutes at 4uC and the aqueous layer was
transferred into new tubes. One volume of 70% ethanol was added
to one volume of the aqueous layer and transferred to an RNeasy
minicolumn (RNeasy mini kit, Qiagen, Valencia, CA) following
the manufacturer’s recommendations. On-column DNase treat-
ment was carried out to remove any contaminating DNA (RNase-
Free DNase Set, Qiagen, Valencia, CA). Total RNA was eluted in
30 ml RNase-free water and stored at 280uC. RNA was extracted
from each sample 2–3 independent times and was assessed for
quality by measuring actin beta expression (assay number
Hs99999903_m1, Applied Biosystems, Foster City, CA) using a
one-step real-time quantitative reverse transcription (RT) PCR as
detailed below.
Real-Time Quantitative RT-PCR. Amplification of specific
cell free mRNA of the 18 genes selected for analysis was conducted
using a one-step real-time quantitative RT-PCR with specific
primers and probe for each gene of interest. One step RT-PCRs
were set up according to the manufacturer’s instructions (EZ rTth
RNA PCR reagent set, Applied Biosystems, Foster City, CA) in a
reaction volume of 20 ml. In detail, 5 ml extracted plasma RNA
was amplified using various Taqman assays consisting of
appropriate probe and PCR primers (Table S2A–B, Applied
Biosystems, Foster City, CA). The RT-PCR thermal profile used
for all primers designed was as follows: The reaction was initiated
at 50uC for 2 minutes to allow the uracil N-glycosylase to become
active, followed by reverse transcription at 60uC for 30 minutes
and a 5 minute denaturation at 95uC. Next, 50 cycles of PCR
were carried out as follows: 20 seconds of denaturation at 94uC
followed by 1 minute of annealing/extension at 60uC. Each
plasma RNA sample was analyzed for the expression of the 18
selected genes in duplicates, from at least two independent RNA
extractions. To correct for differences in both RNA quality and
quantity between samples, data were normalized using the Delta
Ct method in which the ratio of the target gene cycle threshold
(Ct) to the Ct of actin beta was calculated for each sample (Table
S3A). As all 18 genes, including the normalizator actin beta, were
measured simultaneously in the same assay for each RNA sample,
relative quantification and not absolute quantification approach
was utilized. Following normalization of each sample for actin beta
(Delta Ct), the comparative threshold cycle (2‘ Delta-Delta Ct)
method was used to calculate the fold-change of the different genes
relative to a calibrator (Table S3B). RNA extracted from human
leukemia cell line, k-562 cells (ATCC CCL-243), which expresses
all target genes, served repeatedly as a positive control (Delta-Ct
values (average6STDEV) are presented in the bottom of Table
S3) and a calibrator in each and every assay (i.e., calibrators are
assigned a value of 1 by definition). No template controls (NTC)
were also included in every analysis for each gene.
Statistical analysis. Hypoxic pregnancies were compared to
normal pregnancies using chi-square tests or Fisher’s exact test for
categorical variables, t-tests for numerical variables with normal
distributions and the Wilcoxon test for numerical variables with
non-normal distributions. Multivariate logistic regression was used
to study the joint effects of variables in distinguishing between
hypoxic and normal pregnancies. Possible relationships of
numerical variables to genetic markers were explored using
analysis of covariance (ANCOVA), adjusting for the type of
pregnancy (hypoxic or normal). For outcomes that did not meet
the ANCOVA assumptions (normal distribution and constant
error variance), p-values were determined by the bootstrap. In all
analyses, p-values,0.05 were considered statistically significant.
Results
Characteristics of the hypoxic and control groups
132 samples were included in the study cohort (Table S1). 19
twin pregnancies were evaluated by a separate analysis. A total of
113 blood samples from pregnant women, 72 samples from
healthy pregnancies (marked as normal, N) and 41 from
complicated pregnancies (marked as hypoxic, H) were analyzed
(Table S4). There was no age difference between the groups
(p=0.197). Birth week, median adjusted fetal weight (centile) and
median adjusted birth weight were, as expected, significantly lower
in the hypoxic group (p,0.001).
High frequency of p21 and hif1a positive expressions in
hypoxic versus normal pregnancies
Eighteen genes were selected for analysis in this study (Table
S2), with 13 genes not expressed in all samples. Transcripts of 5
genes including p21, hif1a, mdm2, VEGF and ERCC5 were
detected in the cell free maternal plasma samples and were chosen
for further assessment. The relative expression level of p21, hif1a,
Circulating Cell Free mRNA in Hypoxic Pregnancies
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Delta Ct method (Table S3B), was similar between normal and
complicated pregnancies (p.0.05), however there was a clear
difference in the frequency of positive/negative expressions of
several genes between the two groups. As the aim of this study was
to discover a possible marker that will differentiate best between
complicated and normal pregnancies, we were interested in
identifying genes that are expressed with higher incidence in
complicated pregnancies. We therefore focused on analyzing the
differences between the two groups by a categorical positive
(marked by +) or negative (marked by 2) gene expression (Table
S1).
Chi square (x
2) tests were carried out to compare the prevalence
of expression of these genes in the hypoxic and control groups
(Table 1). Significantly higher frequency of positive p21 and hif1a
expression was observed in hypoxic (76% and 49%, respectively)
versus normal pregnancies (25% and 21%, respectively). The
increased occurrence of positive p21 expression in the hypoxic
group was highly significant (p,0.001). Similarly, analysis for
hif1a expression indicated a significantly higher frequency of
positive expression in the hypoxic group (p,0.001). There was no
significant difference between the hypoxic and the normal groups
regarding VEGF, mdm2 and ERCC5 genes.
A correlation between hif1a expression and p21 expression was
evident, as indicated in the joint distribution table (Table 2). In
order to determine whether the expression of p21 and hif1a are
independently associated with hypoxic cases, a multivariate logistic
regression was performed. A significant model has emerged with a
highly significant effect for p21 (p,0.001) and a borderline
significant effect for hif1a (p=0.055), implying that, given the
information on p21, there is not much additional information from
determining hif1a.
An association between currently used parameters for
detection of complicated pregnancies and the different
genes expression
Next, the relationships between the different genes (expressing
versus not expressing) and fetal and maternal clinical character-
istics (Table S1) were analyzed. Among the common parameters
used to detect preeclampsia or complicated pregnancies are
maternal blood hypertension, presence of proteinuria, abnormal
fetoplacental blood flow, measured by fetoplacental Doppler and
IUGR. Logistic regression analysis was used on the full data to
investigate whether distributions of the various categorical
variables differ from samples expressing or not expressing the
different genes in the maternal plasma. Results, depicted in
Table 3, indicate significant association between hypertension
and hif1a (p,0.04), VEGF (p,0.03) and ERCC5 (p,0.02)
expression in the maternal plasma. Urine protein, abnormal
fetoplacental Doppler and IUGR did not reach significant values
among all genes tested. For outcomes that did not meet the
ANCOVA assumptions (normal distribution and constant error
variance), p-values were determined by the bootstrap (Table 4).
No significant differences were observed for additional parameters
after adjustments of the results for the hypoxia and normal status.
Gene expression in the maternal plasma of twin
pregnancies
The study group included 19 twin pregnancies which were
analyzed separately. There were 10 hypoxic twin pregnancies and
9 normal pregnancies. The prevalence of gene expressions in
normal twin pregnancies versus complicated twin pregnancies, as
defined upon sample collection, were analyzed due to the small
sample sizes by Fisher’s exact test. As indicated in Table 5,
although positive p21 expression was much more common in the
hypoxic twin pregnancies, nevertheless this difference did not
reach statistical significance, most probably due to the small
sample size. No significant differences between the groups were
observed with the expression of the additional genes examined. Table 1. Prevalence of mRNA expressions in normal and
hypoxic pregnancies.
Normal Hypoxic
Gene Expression (n=72) n (%) (n=41) n (%) x2 (p value)
p21 2 54 (75%) 10 (24%)
+ 18 (25%) 31 (76%) ,0.001
Hif1a 2 57 (79%) 21 (51%)
+ 15 (21%) 20 (49%) ,0.001
VEGF 2 55 (76%) 26 (63%)
+ 17 (24%) 15 (37%) NS (0.21)
Mdm2 2 47 (65%) 19 (46%)
+ 25 (35%) 22 (54%) NS (0.16)
ERCC5 2 17 (23%) 6 (15%)
+ 55 (77%) 35 (85%) NS (0.46)
The number of cases (n) and percentage of cases (%) in each group with no
expression (2) and positive expression (+). x
2 tests are shown, significant results
(p,0.05). NS, not significant.
doi:10.1371/journal.pone.0037273.t001
Table 2. Joint distribution of p21 and hif1a in the study
population.
Hif1a (2) Hif1a (+)
p21 (2) 57 7
p21 (+) 25 24
No expression (2), Positive (+).
doi:10.1371/journal.pone.0037273.t002
Table 3. Association between hypertension, proteinuria,
abnormal fetoplacental Doppler and IUGR with the
expressions of the different genes in the maternal plasma.
p values
Gene Hypertension Proteinuria
Abnormal
Doppler IUGR
p21 0.461 0.636 0.318 0.218
Hif1a 0.04 0.929 0.894 0.926
VEGF 0.034 0.797 0.614 0.258
ERCC5 0.024* 0.307 0.098 0.43
Mdm2 0.845 0.468 1 0.292
For p21, hif1a, VEGF and mdm2, logistic regression statistic was used.
*For ERCC, Fisher’s test was used. Significant results (p,0.05) in bold.
doi:10.1371/journal.pone.0037273.t003
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Tissue hypoxia during pregnancy, particularly preeclampsia,
may affect both the mother and the fetus. Several modalities to
diagnose hypoxia related disorders during pregnancy include
biochemical markers such as PIGF [35,36], sFLT1 [35], Endoglin
[37] and PP13 [38]. When combined with maternal history, mean
blood pressure and uterine artery Doppler, a detection rate of
approximately 90% with 10% false positive cases is achieved [39].
As current modalities are not sufficient, more reliable methods for
noninvasive preeclampsia monitoring are under research.
In recent years, plasma cell free RNA has been detected in
various conditions and identification of possible markers, including
for hypoxia during pregnancy are sought [40]. Several laboratories
reported on an association between fetal growth and circulating
RNA in the maternal plasma [41,42,43]. Hypoxia-inducible
factors (HIFs) [6] and p53 [25,26], are key transcriptional
regulators of the hypoxic response. Both hif1a and p53 were
shown to be regulated in placentas of pregnancies complicated by
fetal growth retardation [27,44,45,46]. However, to the best of our
knowledge, all studies to date regarding hif1a and p53 were
performed on placental tissues from mouse models or human
subjects. We hypothesized that in complicated pregnancies, up
regulation of hif1a and p53 pathways will lead to the accumulation
of downstream cell free target genes in the maternal circulation
and may serve as noninvasive diagnosis. This prediction was
supported by our demonstration of an association between
increased incidence of circulating p21 expression, a direct p53
target, as well as hif1a with complicated pregnancies. In
accordance with our results, work done in placental tissues
indicated that while mdm2 expression was not significant, a
correlation with p21 was also documented [45]. They concluded
that this association is reminiscent of that following exposure to
hypoxia, highlighting the correlation of our results with data from
placental tissues and their reliability as a possible tool for
noninvasive diagnosis. Among the genes which did not discrim-
inate between complicated and normal pregnancies in our work as
well as others [47] was VEGF, the main ligand for the VEGF
receptor (VEGFR). These results were unexpected as a significant
difference between the expression of circulating VEGFR in
preeclampsia versus controls was reported [43,47].
The discovery of the presence of placental-derived fetal RNA in
maternal plasma has opened up exciting opportunities for
noninvasive prenatal diagnosis [28,48], not limited by the fetal
gender or genotype. However, maternal serum biomarkers
investigated to date for the evaluation of fetal growth had
suboptimal diagnostic sensitivity and predictive power [49,50].
In our work, a strong association between p21 and hif1a
expression patterns and IUGR was documented, indicating that
p21, with or without hif1a expression, might be a good marker for
hypoxic pregnancies and growth retardation. Finally, as with
singleton pregnancies, p21 expression is much more common in
hypoxic twin pregnancies than in normal twin pregnancies, even
though the cohort size was too small for a statistically significant
result.
To conclude, we present here data suggesting that p21 and
hif1a mRNA plasma expressions may be used as markers for
complicated pregnancies. More work is needed to increase the
assay’s sensitivity for future clinical use.
Supporting Information
Table S1 Characteristics of the study cohort: H, Hypoxia;
N, Normal; NA, Not available; G, Number of pregnancies; P,
Table 4. Relation of clinical data to genes expression in the
presence or absence of hypoxia.
Normal Hypoxia p value
Age Gene 2 + 2 +
p21 33.57 34.22 31.4 32.77 0.8
Hif1a 33.66 34.18 31.4 33.45 0.26
VEGF 33.58 34.23 31.52 33.93 0.2
ERCC5 34.12 33.62 33.5 31.97 0.51
Mdm2 34.34 32.6 32.05 32.35 0.32
Birth week Gene 38.25 38.07 33.67 34.12 0.84
a
p21 38.27 37.84 34.11 33.91 0.59
a
Hif1a 38.15 38.39 34.8 32.55 0.11
a
VEGF 38.19 38.21 35.48 33.68 0.2
a
ERCC5 38.38 37.88 34.53 33.4 0.15
a
Mdm2 38.25 38.07 33.67 34.12 0.84
a
Fetal centile Gene 61.68 49.49 5.6 5.74 0.1
a
p21 60.92 47.64 5.29 6.15 0.21
a
Hif1a 59.22 57.5 5.27 6.47 0.91
a
VEGF 63.35 56.74 4.67 5.88 0.23
a
ERCC5 59.54 57.46 4.65 6.75 0.98
a
Mdm2 61.68 49.49 5.6 5.74 0.1
a
Birth centile Gene 58.31 47.78 4.6 6.81 0.3
a
p21 57.21 47.18 7.29 5.2 0.21
a
Hif1a 55.91 54.94 5.96 6.8 0.95
a
VEGF 63.76 53.18 4.17 6.74 0.28
a
ERCC5 56.32 54.48 5.75 6.95 0.94
a
Mdm2 58.31 47.78 4.6 6.81 0.3
a
Hemoglobin Gene 11.45 11.81 11.42 12.02 0.118
p21 11.48 11.85 11.99 11.7 0.885
Hif1a 11.62 11.26 11.86 11.87 0.472
VEGF 11.78 11.44 11.75 11.82 0.416
ERCC5 11.65 11.31 11.92 11.69 0.243
Mdm2 11.45 11.81 11.42 12.02 0.118
Average of each parameter in the study groups is shown. p-values determined
by the bootstrap are marked by the letter a.
doi:10.1371/journal.pone.0037273.t004
Table 5. Gene’s expression in the maternal plasma of twin
pregnancies.
Normal Hypoxia
Gene 2 + 2 + p value
p21 63 28 0 . 0 7
Hif1a 09 37 0 . 2 1
VEGF 18 73 0 . 5 8
ERCC5 27 37 1
Mdm2 45 73 0 . 3 7
Fisher’s exact test for the expression of the different genes in hypoxia versus
normal twin pregnancies. No expression (2), positive expression (+).
doi:10.1371/journal.pone.0037273.t005
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***, Dollberg 2005.
(PDF)
Table S2 Selected genes induced by (A) hypoxia and (B)
p53.
(PDF)
Table S3 Delta Ct and Delta-Delta Ct calculations for
the study cohort.
(PDF)
Table S4 Analysis of the study population: Significant
results (p,0.05) are highlighted by a grey background. Average
(Avg), standard deviation (SD), interquartile range (IQR), hypoxia
(H), normal (N).
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